Details for New Drug Application (NDA): 070173
✉ Email this page to a colleague
NDA 070173 describes DISOPYRAMIDE PHOSPHATE, which is a drug marketed by Nesher Pharms, Dr Reddys Labs Sa, Interpharm, Ivax Sub Teva Pharms, Mylan, Rising, Sun Pharm Industries, Superpharm, Teva, and Watson Labs, and is included in eighteen NDAs. It is available from three suppliers. Additional details are available on the DISOPYRAMIDE PHOSPHATE profile page.
The generic ingredient in DISOPYRAMIDE PHOSPHATE is disopyramide phosphate. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.
The generic ingredient in DISOPYRAMIDE PHOSPHATE is disopyramide phosphate. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.
Summary for 070173
| Tradename: | DISOPYRAMIDE PHOSPHATE |
| Applicant: | Dr Reddys Labs Sa |
| Ingredient: | disopyramide phosphate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 070173
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DISOPYRAMIDE PHOSPHATE | disopyramide phosphate | CAPSULE;ORAL | 070173 | ANDA | Mayne Pharma Commercial LLC | 51862-095 | 51862-095-01 | 100 CAPSULE in 1 BOTTLE (51862-095-01) |
| DISOPYRAMIDE PHOSPHATE | disopyramide phosphate | CAPSULE;ORAL | 070173 | ANDA | Mayne Pharma Commercial LLC | 51862-096 | 51862-096-01 | 100 CAPSULE in 1 BOTTLE (51862-096-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | May 31, 1985 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 150MG BASE | ||||
| Approval Date: | May 31, 1985 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
